The hypomethylating agents (HMAs) azacitidine (AZA) and decitabine (DAC) improve long-term outcomes of higher-risk (International Prognostic Scoring System [IPSS] intermediate-2 or high) myelodyspl...
No takes yet. Share an insight, caveat, or question.
Itzykson et al. (2011) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: